ASTELLAS PHARMA
๐ฏ๐ตJapan
- Country
- ๐ฏ๐ตJapan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 96
- Registration Number
- NCT01478503
- Locations
- ๐ณ๐ฑ
Kendle Nederland, Utrecht, Netherlands
๐ณ๐ฑPharma Bio Research, Zuidlaren, Netherlands
A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01478529
- Locations
- ๐ณ๐ฑ
Pharma Bio Research, Zuidlaren, Netherlands
A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 468
- Registration Number
- NCT01478607
- Locations
- ๐บ๐ฆ
Site: 806, Kyiv, Ukraine
๐บ๐ฆSite: 802, Mykolayiv, Ukraine
๐ต๐ฑSite: 954, Katowice, Poland
To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478568
- Locations
- ๐ซ๐ท
SGS Aster, Paris, France
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01476800
- Locations
- ๐บ๐ธ
MDS Pharma Services (US) Inc., Lincoln, Nebraska, United States
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 319
- Registration Number
- NCT01451203
Special Drug Use-Results Survey of Lipitor Tablets
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24050
- Registration Number
- NCT01446679
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 21
- Registration Number
- NCT01442337
- Locations
- ๐บ๐ธ
Baylor University Medical Center, Dallas, Texas, United States
๐บ๐ธSt. Vincent Medical Center, Los Angeles, California, United States
๐บ๐ธSharp Memorial, San Diego, California, United States
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01430065
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Miami, Florida, United States
A Study to Assess the Bioavailability of ASP015K
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01430078
- Locations
- ๐ฌ๐ง
Quotient Clinical Limited, Ruddington, Nottingham, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath